290 related articles for article (PubMed ID: 32453265)
1. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
[TBL] [Abstract][Full Text] [Related]
2. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
[TBL] [Abstract][Full Text] [Related]
3. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Small CB; Margolis DA; Shaefer MS; Ross LL
BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
[TBL] [Abstract][Full Text] [Related]
4. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
[TBL] [Abstract][Full Text] [Related]
5. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
[TBL] [Abstract][Full Text] [Related]
6. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
[TBL] [Abstract][Full Text] [Related]
7. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA
Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP
AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
[TBL] [Abstract][Full Text] [Related]
9. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
10. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
[TBL] [Abstract][Full Text] [Related]
11. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
Arnedo Valero M
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
[TBL] [Abstract][Full Text] [Related]
12. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
[TBL] [Abstract][Full Text] [Related]
13. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
[TBL] [Abstract][Full Text] [Related]
14. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
15. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
[TBL] [Abstract][Full Text] [Related]
16. High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.
Siljic M; Salemovic D; Cirkovic V; Pesic-Pavlovic I; Todorovic M; Ranin J; Dragovic G; Jevtovic D; Stanojevic M
Intervirology; 2017; 60(1-2):43-47. PubMed ID: 28772259
[TBL] [Abstract][Full Text] [Related]
17. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
18. Abacavir hypersensitivity reaction: an update.
Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
[TBL] [Abstract][Full Text] [Related]
19. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
20. Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S; Soriano V
Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
